JoEllyn McMillan, PhD

JoEllyn_McMillan

Research Interests
Representative Publication
Biographical Information

JoEllyn McMillan, PhD
Assistant Professor

Durham Research Center 3062
985800 Nebraska Medical Center
Omaha, NE 68198-5800

Phone: 402-559-3093
Fax: 402-559-7495
E-mail: jmmcmillan@unmc.edu

College of Public Health - Faculty Highlight


Keywords: toxicology, environmental, genomics, toxicity mechanisms nanomedicine, drug analysis, cell cultures, antiretroviral drugs, anti-cancer drugs, anti-inflammatory drugs, antimalarial drugs, hemolytic anemia

Research Interests:

My Research interests and training have been in the field of toxicology. Past research areas have involved the use of cell and whole animal models to study mechanisms of liver toxicity of drugs and environmental chemicals.

Presently, in collaboration with others in Dr. Howard Gendelman's laboratory, I am using HPLC to analyze drug levels in studies on cell uptake and delivery of nanoformulations of drugs used to treat various neurological diseases. These collaborative studies are part of a project to develop methods to deliver nanoformulations of drugs for treatment of diseases such as AIDS-associated dementia, glioma and Parkinson's disease.

In collaboration with Dr. David McMillan and Walter Reed Army hospital, we are determining the dose-limiting side effects of derivatives of the antimalarial drug primaquine using a rodent model for hemolytic anemia. Current therapies are becoming increasingly ineffective due to the development of drug resistance by the parasite. Development of more effective drugs has been limited by the induction of drug-induced hemolytic anemia in sensitive populations. Our studies are part of a group effort to develop new antimalarial drugs with little to no dose-limiting side effects.


Representative Publications

  1. Nowacek, A.S., McMillan, J., Miller, R., Anderson, A., Rabinow, B., Gendelman, H.E. Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for NeuroAIDS Therapeutics. J. Neuroimmune Pharmacolo. 2010 5(4)-
  2. Nowacek, A.S., Miller, R.L., McMillan, J., Kanmogne, G., Kanmogne, M., Mosley, R.L., Ma, Z, Graham, S., Chaubal, M., Werling, J., Rabinow, B., Dou, H., Gendelman, H.E. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine, 2009 4(8):903-17
  3. Dou, H., Grotepas, C.B., McMillan, J.M., Boska, M.D., Chaubal, M., Werling, J., Kipp, J., Rabinow, B., Gendelman, H.E., Macrophage delivery of nanoformulated anti retroviral drug to the brain in a murine model of neuroAIDS. J. Immunol. 2009 Jul 1;183(1):661-9
  4. Ierardi, J.L, Mancia, A., McMillan, J.M., Lundqvist, M.L., Romano, T.A., Wise, J.P. Sr., Warr, G.W., Chapman, R.W. Sampling the skin transcriptome of the North Atlantic right whale. Comp. Biochem. Physiol. Part D: Genomics and Proteomics., 2009
  5. Lock, E.A., Reed, C.J., McMillan, J.M., Oatis, J.R., and Schnellmann, R.G. Lack of formic acid production in rat hepatocytes and human renal proximal tubule cells exposed to chloral hydrate or trichloroacetic acid. Toxicology. 230: 234-243, 2007
  6. McMillan, J.M., and McMillan, D.C. S-Adenosylmethionine but not glutathione protects against galactosamine-induced cytotoxicity in rat hepatocyte cultures. Toxicology. 222: 175–184, 2006

Additional publications on PubMed

return to top of page


Dr. JoEllyn McMillan's biographical information